Apellis Pharmaceuticals, Inc.

Informe acción NasdaqGS:APLS

Capitalización de mercado: US$4.9b

Salud financiera de hoja de balance de Apellis Pharmaceuticals

Salud financiera controles de criterios 3/6

Apellis Pharmaceuticals tiene un patrimonio de los accionistas total de $266.7M y una deuda total de $93.1M, lo que sitúa su ratio deuda-patrimonio en 34.9%. Sus activos y pasivos totales son $831.9M y $565.3M respectivamente.

Información clave

34.9%

Ratio deuda-patrimonio

US$93.11m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$333.54m
PatrimonioUS$266.68m
Total pasivoUS$565.25m
Activos totalesUS$831.93m

Actualizaciones recientes sobre salud financiera

Recent updates

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30
What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30
It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19
With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13
Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Nov 09
Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise

Sep 28

Apellis gains as FDA says AdCom unnecessary for eye disease candidate

Sep 07

Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?

Aug 17
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?

Apellis to exchange $75.6M in convertible senior notes for common stock

Jul 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($811.4M) de APLS superan a sus pasivos a corto plazo ($215.3M).

Pasivo a largo plazo: Los activos a corto plazo de APLS ($811.4M) superan a sus pasivos a largo plazo ($350.0M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: APLS tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de APLS ha crecido de 3% a 34.9% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: APLS tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si APLS tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera